Completed PHASE3 NCT01765179

Safety and Efficacy Trial of Testosterone Undecanoate

Phase III, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU)in Hypogonadal Men

Sponsor: Clarus Therapeutics, Inc.

Interventions Oral testosterone undecanoate

Updated 8 times since 2017 Last updated: Nov 14, 2017 Started: Jan 31, 2013 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This PHASE3 trial investigates Male Hypogonadism and is currently completed. Clarus Therapeutics, Inc. leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Oct 2017 — Dec 2017 [monthly]

Completed PHASE3
Feb 2017 — Oct 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clarus Therapeutics, Inc.
inVentiv Health Clinical

Data source: Clarus Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aventura, United States , Bala-Cynwyd, United States , Birmingham, United States , Brandon, United States , Carrollton, United States , Clearwater, United States , Dallas, United States , Garden Grove, United States , Glendale, United States , Houston, United States and 15 more locations